Spinal Muscular Atrophy 1 Clinical Trial
Official title:
A Multicenter, Open, Dose-escalation Clinical Study Evaluating the Safety, Initial Efficacy, and Immunogenicity of SKG0201 Injection in Patients With Spinal Muscular Atrophy Type 1
This is a clinical study to evaluate the safety and efficacy of gene therapy drug SKG0201 Injection in patients with spinal muscular atrophy Type 1 (SMA 1).
This is a multicenter, open, dose-escalation clinical study to evaluate the safety, initial efficacy, and immunogenicity of SKG0201 injection in patients with spinal muscular atrophy type 1 (SMA 1). ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT03421977 -
Long-Term Follow-up Study for Patients From AVXS-101-CL-101
|
||
| Completed |
NCT02122952 -
Gene Transfer Clinical Trial for Spinal Muscular Atrophy Type 1
|
Phase 1 | |
| Completed |
NCT01862042 -
Palliative Care in Spinal Muscular Atrophy (SMA) 1
|
N/A |